# Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma

> **NCT06470217** · PHASE2 · RECRUITING · sponsor: **Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University** · enrollment: 116 (estimated)

## Conditions studied

- Locally Advanced Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** tirilizumab with albumin-bound paclitaxel and cisplatin
- **PROCEDURE:** surgery

## Key facts

- **NCT ID:** NCT06470217
- **Lead sponsor:** Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-19
- **Primary completion:** 2025-06-19
- **Final completion:** 2027-06-19
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06470217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06470217, "Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06470217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*